Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Bionime Corporation (4737.TW)
Taichung, TW
Bionime Corporation, headquartered in Taichung, Taiwan, specializes in the development, production, and global distribution of medical instruments. The company maintains a significant international presence, serving markets in countries such as China, Switzerland, the United States, Algeria, and Egypt. Its primary product line features blood glucose monitoring systems, along with essential complementary items like test strips and lancing devices. These healthcare solutions are supplied to a varied customer base, including hospitals, pharmacies, and other medical equipment enterprises. Beyond its core medical device business, Bionime also engages in providing biotechnology-related services, performing pharmaceutical analysis, and marketing high-precision tools. The company was founded in 2003.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -5.94% | -3.39% | -14.93% | +4.78% | -8.06% | -3.28% | -8.55% | -18.12% | -6.50% | +32.71% | -39.02% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Instruments & Supplies: +7.9%-4.9% Q1'26: -15.8% (vs Q1'25)
-
EPS growth Medical - Instruments & Supplies: +16.3%-38.8% Q1'26: -471.0% (vs Q1'25)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%+16.3% Q1'26: -3.7% (vs Q1'25)
-
EBIT margin Medical - Instruments & Supplies: +13.5%-10.7% Q1'26: -21.8% (vs Q1'25)
-
ROIC Medical - Instruments & Supplies: +6.0%-4.6% Q1'26: -6.4% (vs Q1'25)
-
Share dilution Medical - Instruments & Supplies: +0.1%+1.4% Q1'26: +11.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×-202.93× Q1'26: -14.77× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.61B
est: 1.61B (+0.0%)
|
1.74B
est: 1.73B (+0.4%)
|
1.82B
est: 1.85B (-1.6%)
|
2.01B
est: 2.07B (-3.0%)
|
2.17B
est: 2.08B (+4.3%)
|
1.67B
est: 2.29B (-27.2%)
|
1.85B
est: 2.05B (-9.8%)
|
2.21B
est: 2.21B (-0.1%)
|
1.76B
est: 1.76B (0.0%)
|
1.93B
est: 2.10B (-7.8%)
|
| EBITDA |
334.32M
est: 167.12M (+100.0%)
|
394.33M
est: 179.97M (+119.1%)
|
357.79M
est: 191.97M (+86.4%)
|
342.34M
est: 214.81M (+59.4%)
|
330.84M
est: 216.27M (+53.0%)
|
216.15M
est: 238.07M (-9.2%)
|
248.29M
est: 213.05M (+16.5%)
|
270.36M
est: 229.66M (+17.7%)
|
179.78M
est: 182.32M (-1.4%)
|
59.29M
est: 160.03M (-63.0%)
|
| EBIT |
180.97M
est: 25.95M (+597.4%)
|
236.32M
est: 27.95M (+745.7%)
|
212.00M
est: 29.81M (+611.2%)
|
191.01M
est: 33.35M (+472.7%)
|
166.36M
est: 33.58M (+395.4%)
|
52.66M
est: 36.97M (+42.5%)
|
93.64M
est: 33.08M (+183.1%)
|
117.13M
est: 35.66M (+228.5%)
|
16.36M
est: 28.31M (-42.2%)
|
-123.52M
est: -24.46M (-405.0%)
|
| Net Income |
98.79M
est: 158.82M (-37.8%)
|
178.79M
est: 135.94M (+31.5%)
|
149.61M
est: 156.81M (-4.6%)
|
128.03M
est: 132.80M (-3.6%)
|
106.26M
est: 110.26M (-3.6%)
|
62.43M
est: 34.12M (+83.0%)
|
87.41M
est: 67.01M (+30.4%)
|
91.03M
est: 129.15M (-29.5%)
|
6.21M
est: 12.18M (-49.0%)
|
-127.22M
est: 72.78M (-274.8%)
|
| SGA |
393.73M
est: 467.26M (-15.7%)
|
371.70M
est: 503.19M (-26.1%)
|
387.40M
est: 536.74M (-27.8%)
|
476.52M
est: 600.60M (-20.7%)
|
526.85M
est: 604.67M (-12.9%)
|
456.85M
est: 665.63M (-31.4%)
|
540.54M
est: 595.67M (-9.3%)
|
641.15M
est: 642.11M (-0.2%)
|
523.17M
est: 509.74M (+2.6%)
|
575.11M
est: 588.45M (-2.3%)
|
| EPS |
1.74
est: 2.37 (-26.7%)
|
2.56
est: 2.03 (+26.4%)
|
2.29
est: 2.34 (-2.1%)
|
2.03
est: 1.98 (+2.3%)
|
1.68
est: 1.65 (+2.2%)
|
0.96
est: 0.51 (+89.3%)
|
1.33
est: 1.00 (+32.7%)
|
1.36
est: 1.93 (-29.3%)
|
0.09
est: 0.18 (-50.0%)
|
-1.91
est: 1.07 (-278.2%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 80.4K | 0.39% |
| 2 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 43.7K | 0.28% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Chun-Mu Huang | Founder, Chairman & GM | 3M | male |
| Hui-Zhen Chen | Assistant GM of Administration Division & Corporate Governance Officer | — | female |
| Ming-Lun Zhang | Assistant General Manager of Marketing Planning Division | — | male |
| Sherry Huang | Manager of Human Resources Department & Financial Officer | — | — |
| Ya-Wen Chen | Accounting Supervisor | — | female |
| Yu-Jen Hsiu | Assistant General Manager of Operation Division | — | male |
| Cheng-Hong Shi | Assistant General Manager of Sales Division | — | male |
| Zhen Teng Xu | Vice President of Research and Development | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4737.TW
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
